Skip navigation
Clinical Data for Acyline - presented at the AACR - NCI - EORTC International Conference on "Molecular Targets and Cancer Therapeutics" on the 24th Oct 2007 in San Francisco.
Acyline (MER-104)
Print page
Email pageClinical Data for Acyline - presented at the AACR - NCI - EORTC International Conference on "Molecular Targets and Cancer Therapeutics" on the 24th Oct 2007 in San Francisco.
Acyline is in development for Oncology and other indications
Acyline is an oral GnRH antagonist using GIPET® technology and provides an oral dosage form alternative to current therapies, all of which are injectable. GnRH antagonists are marketed for the treatment of prostate cancer and endometriosis.
An oral product would eliminate the inconvenience of injection therapy, avoid the severe reactions, and allow tailored dosing regimens. Acyline is a potent GnRH antagonist with an attractive product profile for development as an oral dosage form.